Skip to main content
Przejdź do strony domowej Komisji Europejskiej (odnośnik otworzy się w nowym oknie)
polski pl
CORDIS - Wyniki badań wspieranych przez UE
CORDIS

Engineered hyaluronic acid hydrogel for enhanced EV retention and controlled release

Cel

Extracellular vesicles (EVs) are rapidly emerging as a next-generation therapeutic modality in regenerative medicine and immunomodulation. However, a major translational limitation is their rapid dispersion and clearance following administration. Existing hydrogel delivery systems typically rely on physical encapsulation in gels developed for other biomedical applications, or chemical/ genetic modification of EVs to tether them to hydrogels to achieve retention. Such approaches lack control over EV release, or can alter EV surface properties, complicate manufacturing, and restrict compatibility to specific EV types. To address this problem, GelEV aims to validate a novel hyaluronic acid (HA)-based hydrogel that enhances EV retention without requiring EV surface modification or encapsulation. This bio- and cyto-compatible platform incorporates hydrogel modifications to prolong local EV availability while preserving native EV structure and function. By avoiding EV modification steps, the system is designed to be compatible with diverse EV sources and manufacturing pipelines. Thus far, this novel hydrogel demonstrates increased retention of murine MSC-derived EVs. This project will de-risk the technology by verifying hydrogel manufacturability and by validating compatibility with clinically relevant human, lyophilised, and commercially available EV formulations. Functional assays will confirm preservation of bioactivity following sustained release. The development of an EV-agnostic hydrogel delivery platform will create an enabling technology for the expanding EV therapeutics sector. If successful, the licensable platform will allow EV developers to enhance therapeutic performance by having a controlled EV delivery tool, without altering their EV products, thereby accelerating clinical translation across multiple regenerative and inflammatory indications for patients, positioning it for commercial adoption in research and pharmaceutical contexts.

Dziedzina nauki (EuroSciVoc)

Program(-y)

Temat(-y)

System finansowania

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Wyświetl wszystkie projekty finansowane w ramach tego programu finansowania

Zaproszenie do składania wniosków

(odnośnik otworzy się w nowym oknie) ERC-2026-POC

Wyświetl wszystkie projekty finansowane w ramach tego zaproszenia

Instytucja przyjmująca

UNIVERSITY OF GALWAY
Wkład UE netto
€ 150 000,00
Koszt całkowity
Brak danych

Beneficjenci (1)